Core Insights - Psyence Biomedical Ltd. announced that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract, meeting food-grade microbial safety standards verified by a third-party laboratory [1][3][4] - The company has continued its investment in PsyLabs, reflecting its commitment to supporting the development of scalable and compliant psychedelic APIs [1][4] - PsyLabs aims to further increase purity levels of its products, including Ibogaine HCL and Psilocybin Isolate, to meet growing global demand [2][4] Company Overview - PsyLabs is a federally licensed psychedelic Active Pharmaceutical Ingredient (API) development company, focusing on the cultivation, extraction, and export of various psychedelic compounds to legal medical and research markets [6][7] - The company has successfully exported psilocybin products to multiple countries, including Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner [6][7] - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, being the first life sciences biotechnology company focused on nature-derived psilocybin and ibogaine to be listed on Nasdaq [7]

Core Insights - Psyence Biomedical Ltd. has established a Scientific Advisory Board (SAB) to enhance its expertise in psilocybin research and clinical trial design [1][3] - Dr. Albert P. Garcia-Romeu, a prominent researcher in psychedelics, will chair the SAB, bringing significant experience in psilocybin clinical trials [2][3] - The company is advancing its Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and is preparing for a second indication in Alcohol Use Disorder [3][4] Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, specifically nature-derived psilocybin [4] - The company aims to address unmet needs in mental health disorders, particularly in the context of Palliative Care [4] - Psyence is the first life science biotechnology company developing psilocybin-based psychedelic medicine to be listed on Nasdaq [4] Research and Development - The SAB will assist in designing the Phase III program for Adjustment Disorder while also preparing for Alcohol Use Disorder development [3] - Dr. Garcia-Romeu's involvement is expected to enhance the company's research capabilities in areas that have been largely overlooked by the pharmaceutical industry [4]